WHY IT MATTERS: Patients and caregivers exploring cannabinoid options for neurological conditions should understand that while the basic science is genuinely promising, the gap between preclinical findings and proven clinical treatments means these approaches are best pursued under informed medical guidance rather than based on headlines alone. CLINICAL OVERVIEW: The endocannabinoid system plays a fundamental role in regulating neuronal health, modulating inflammation, oxidative stress, and cell survival pathways that are central to neurodegenerative disease processes. Non-psychoactive cannabinoids such as CBD, CBG, and CBDV interact with receptors and signaling cascades throughout the central nervous system in ways that may slow or interrupt the progression of conditions like Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury sequelae.
Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC
WHY IT MATTERS: Patients with fatty liver disease or metabolic syndrome may eventually have access to cannabinoid-based therapies as an adjunct treatment option, but only after human clinical trials confirm the safety and efficacy signals seen in early research. CLINICAL OVERVIEW: Emerging preclinical research is examining how non-psychoactive cannabinoids, particularly CBD and CBG, may influence hepatic lipid metabolism and reduce fat accumulation in liver tissue. These compounds appear to interact with endocannabinoid receptors and metabolic pathways involved in fatty acid synthesis and inflammation, offering a potential therapeutic avenue for metabolic-associated steatotic liver disease.
0 days without (Lenny, Simpsons)
When your patient swears they haven’t used cannabis in months, but the urinalysis disagrees with their timeline. Further Reading Cannabis NewsRecreational drugs triple the risk of stroke in young people, study finds...
Batman Slapping Robin
“Maybe we should try CBD for inflammation.” Batman: “That’s literally what the clinical evidence supports.” Robin gets slapped anyway because evidence-based medicine is apparently still controversial. Further Reading Cannabis NewsRecreational drugs triple...
Feds warn about medical cannabis & hemp in drug tests (Newsletter: March 6, 2026)
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicySafetyResearchHemp Why This Matters Clinicians need to counsel patients that medical cannabis use can trigger...
Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. NeurologyResearchAgingSafety Why This Matters Clinicians counseling older adult patients about cannabis use can now reference...
Daily Digest: Last 24 Hours: Cognitive Safety in Older Adults, End-of-Life Access, and the Regulatory Gaps That Still Hurt Patients — March 06, 2026
A synthesis of 68 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
In the Mix: 3 More Articles — March 05, 2026
3 cannabis articles scored below the CED clinical relevance threshold in the last 24 hours. Summaries and source links included.
Daily Digest: Last 9 Hours: Cognitive Safety Data, End-of-Life Access, and Regulatory Friction — March 05, 2026
A synthesis of 68 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Ohio Department of Commerce recalls certain marijuana gummies lacking THC symbol
✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicySafetyTHCIndustry Why This Matters This recall highlights the importance of proper product labeling and quality...